Piraccini Topical Finasteride Phase III: Key Findings Explained in Plain Language
Topical finasteride reduced scalp DHT comparably to oral finasteride while maintaining significantly lower systemic blood levels of the drug.
Study overview
Conducted by
Dr. B.M. Piraccini et al., multi-center European trial
Patients
Men with androgenetic alopecia (Phase III design)
Duration
24 weeks
Published in
Journal of the American Academy of Dermatology
Year
2022
Key findings
Scalp DHT reduction comparable to oral finasteride
Topical application achieved similar DHT suppression at the follicle level as the standard 1mg oral dose. The drug reached the target tissue effectively via topical delivery.
Systemic blood levels significantly lower
Blood finasteride concentrations with topical application were a fraction of those seen with oral dosing. This matters because systemic exposure is what drives the sexual side effects some men experience.
Hair regrowth comparable to oral finasteride
Clinical efficacy -- measured by hair count and investigator assessment -- was not meaningfully different between topical and oral routes.
Improved side effect profile
The lower systemic exposure translated to a lower incidence of systemic side effects compared to historical data on oral finasteride.
What this means for you
This study validates the topical finasteride approach. You get the same DHT-blocking benefit at the scalp -- which is where it matters for hair loss -- with much less drug circulating through your bloodstream. This is why LYV uses topical finasteride rather than oral: same efficacy where it counts, lower systemic risk.
Limitations
The 24-week duration is shorter than the Kaufman 5-year oral finasteride study. Direct long-term comparisons between topical and oral finasteride are limited. The study focused on men; women were not included. Topical application requires consistent daily use and proper technique.
See if this compound is right for your goals
Take a 2-minute quiz. Get a personalized protocol.